About
ATMPs are the next revolution in medicine promising a leap in survival, quality of life and cure for cancer patients. Although many novel ATMPs are under development in academic centers, the steps toward market approval and clinical application are complex and do not fit the traditional frameworks. To form such framework, DARE-NL was established. Funded by the Dutch Cancer Society (KWF) (€5,3 million), DARE-NL aims to accelerate clinical testing of novel ATMPs for cancer patients to ensure timely and sustainable access to potentially curative treatment options for cancer patients. To achieve this DARE-NL aims to focus on three domains:
Connecting
- Translational ATMP experts from academic centers throughout the Netherlands
- Policy makers and regulory scientists in the Netherlands and EU through centralized dialogues
- Existing (inter)national ATMP organisations
Harmonizing
- Exchanging procedures such as manufacturing processes and QC assays between partners within DARE-NL
- Mapping and assessing the needs for next-generation technologies required for improved ATMP production
Facilitating
- Establishing an overview of key Good Manufacturing Practice (GMP) ingredienst for adacemic manufacturing of ATMPs
- Organizing events, webinars, and workshops to spread information.
- Educate and create networking opportunities between academia, industry and patients organisations.
To build and expand upon these domains, a unique collaborative effort between all Dutch university medical centers, NKI-AVL, Princess Máxima Center, Sanquin and Utrecht University is established. The main teams that manage and steer the project are as following:
- The management team comprises project leaders Trudy Straetemans (UMC Utrecht), Harry Dolstra (Radboudumc), Edwin Bremer (UMC Groningen) and Inge Jedema (NKI-AVL).
- The project team consisting of experts from different centers specialized for each work package
- The steering committee comprises representative renowned translational tumor immunologists and ATMP developers from all 11 centers.
- Scientific Advisory Board with international renowned and leading scientists provides external advice on direction and progress of DARE-NL.
- Patient Advisory Board comprising representatives of various patient organisations.
- Patient Participation Review committee comprising of patient representatives that review the involvement of patients
DARE-NL is supported by a large team of scientists, pharmacists, clinicians, regulatory science, health economic and IP/business development experts from all member institutes in the different work packages. Many ATMP working groups, agencies, consortia, platforms and networks are represented or consulted by DARE-NL members. The combined expertise in academic development and production of ATMPs is crucial for DARE-NL to be successful.
If you are interested in our mission and have any questions you can contact us.
Supporting organizations
